Biogen gears up Swiss manufacturing facility for potential aducanumab rollout

7th May 2020 Uncategorised 0

Biogen has had a rocky road with its controversial Alzheimer’s disease candidate aducanumab, resurrected late last year. But despite postponing the drug’s FDA filing half a year, Biogen is still moving forward with plans to scale up production if aducanumab eventually passes muster.

More: Biogen gears up Swiss manufacturing facility for potential aducanumab rollout
Source: fierce